Erythropoietin slows photoreceptor cell death in a mouse model of autosomal dominant retinitis pigmentosa

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Rex, Tonia S ^a   Kasmala, Lorraine ^a   Bond, Wesley S ^a   De Lucas Cerrillo, Ana M ^a   Wynn, Kristi ^a   Lewin, Alfred S ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; GREEN FLUORESCENT PROTEIN; PARVOVIRUS VECTOR; RHODOPSIN; OPSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG ACTIVITY; ELECTRORETINOGRAM; ERYTHROPOIETIC ACTIVITY; GENE REPLACEMENT THERAPY; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; RETINA ROD; RETINAL OUTER NUCLEAR LAYER; RETINITIS PIGMENTOSA; ANIMAL; CELL DEATH; DEPENDOPARVOVIRUS; DISEASE MODEL; GENE THERAPY; GENE TRANSFER; GENETICS; HUMAN; PATHOLOGY; PATHOPHYSIOLOGY; POINT MUTATION; RETINA CONE; VISION;

ANIMALS; CELL DEATH; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; MICE; OPSINS; POINT MUTATION; RETINAL CONE PHOTORECEPTOR CELLS; RETINITIS PIGMENTOSA; VISION, OCULAR;

EID: 84976353288     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157411     Document Type: Article

References (43)

1. RetNet. 1996-2009; Available from: http://www.sph.uth.tmc.edu/retnet/.
2. Dryja T., McGee T., Hahn L., Cowley G., Olsson J., Reichel E., et al., Mutations within the rhodopsin gene in patients with autosomal dominant retinitis pigmentosa. New England Journal of Medicine, 1990. 323: p. 1302-1307. PMID: 2215617
3. Sung C., Davenport C., Hennessey J., Maumenee I., Jacobson S., Heckenlively J., et al., Rhodopsin mutations in autosomal dominant retinitis pigmentosa. Proceedings of the National Academy of Sciences USA, 1991. 88: p. 6481-6485.
4. Dryja T., McEvoy J., McGee T., and Berson E., Novel rhodopsin mutations Gly114Val and Gln184Pro in dominant retinitis pigmentosa. Investigative Ophthalmology & Vision Science, 2000. 41: p. 3124-3127.
5. Noorwez S., Ostrov D., McDowell J., Krebs M., and Kaushal S., A high-throughput screening method for small-molecule pharmacologic chaperones of misfolded rhodopsin. Investigative Ophthalmology & Vision Science, 2008. 49: p. 3224-3230.
6. Nguyen A., Campbell M., Kiang A., Humphries M., and Humphries P., Current therapeutic strategies for P23H RHO-linked RP. Advances in Experimental Medicine and Biology, 2014. 801: p. 471-476. doi: 10.1007/978-1-4614-3209-8-60 PMID: 24664733
7. Chiang W., Kroeger H., Sakami S., Messah C., Yasumura D., Matthes M., et al., Robust endoplasmic reticulum-associated degradation of rhodopsin precedes retinal degeneration. Molecular Neurobiology, 2015. 52: p. 679-695. doi: 10.1007/s12035-014-8881-8 PMID: 25270370
8. Mao H., James T.J., Schwein A., Shabashvili A., Hauswirth W., Gorbatyuk M., et al., AAV delivery of wild-type rhodopsin preserves retinal function in a mouse model of autosomal dominant retinitis pigmentosa. Human Gene Therapy, 2011. 22: p. 567-575. doi: 10.1089/hum.2010.140 PMID: 21126223
9. Gupta N., Brown K., and Milam A., Activated microglia in human retinitis pigmentosa, late-onset retinal degeneration, and age-related macular degeneration. Experimental Eye Research, 2003. 76: p. 463-471. PMID: 12634111
10. Fernandez-Sanchez L., Lax P., Campello L., Pinilla I., and Cuenca N., Astrocytes and Muller cell alterations during retinal degeneration in a transgenic rat model of retinitis pigmentosa. Frontiers in Cellular Neuroscience, 2015. 9: p. 484. doi: 10.3389/fncel.2015.00484 PMID: 26733810
11. Sargin D., Friedrichs H., El-Kordi A., and Ehrenreich H., Erythropoietin as neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 years of preclinical and clinical research. Best Practices in Research and Clinical Anaesthesiology, 2010. 24: p. 573-594.
12. Digicaylioglu M., Bichet S., Marti H., Wenger R., Rivas L., Bauer C., et al., Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proceedings of the National Academy of Sciences USA, 1995. 92: p. 3717-3720.
13. Bond W. and Rex T., Evidence that erythropoietin modulates neuroinflammation through differential action on neurons, astrocytes, and microglia. Frontiers in Immunology, 2014. 5: p. 523. doi: 10.3389/ fimmu.2014.00523 PMID: 25374571
14. Marrero M., Venema R., Ma H., Ling B., and Eaton D., Erythropoietin receptor-operated Ca2+ channels: activation by phospholipase C-gamma 1. Kidney Int., 1998. 53: p. 1259-1268. PMID: 9573541
15. Zhao H., Wang R., Wu X., Liang J., Qi Z., Liu X., et al., Erythropoietin delivered via intra-arterial infusion reduces endoplasmic reticulum stress in brain microvessels of rats following cerebral ischemia and reperfusion. Journal of Neuroimmune Pharmacology, 2015. 10: p. 153-161. doi: 10.1007/s11481-014-9571-z PMID: 25626440
16. Rex T., Wong Y., Kodali K., and Merry S., Neuroprotection of photoreceptors by direct delivery of erythropoietin to the retina of the retinal degeneration slow mouse. Experimental Eye Research, 2009. 89: p. 735-740. doi: 10.1016/j.exer.2009.06.017 PMID: 19591826
17. Hines-Beard J., Bond W., Backstrom J., and Rex T., Virus-mediated EpoR76E gene therapy preserves vision in a glaucoma model by modulating neuroinflammation and decreasing oxidative stress. Journal of Neuroinflammation, 2016. 13: p. 39. doi: 10.1186/s12974-016-0499-5 PMID: 26876380
18. Rex T., Allocca M., Domenici L., Surace E., Maguire A., Lyubarsky A., et al., Systemic but not intraocular Epo gene transfer protects the retina from light-and genetic-induced degeneration. Mol Ther., 2004. 10(5): p. 855-861. PMID: 15509503
19. Sullivan T., Geisert E., Hines-Beard J., and Rex T., Systemic AAV-mediated gene therapy preserves retinal ganglion cells and visual function in DBA/2J glaucomatous mice. Human Gene Therapy, 2011. 22: p. 1191-1200. doi: 10.1089/hum.2011.052 PMID: 21542676
20. Sullivan T., Geisert E., Templeton J., and Rex T., Dose-dependent treatment of optic nerve crush by exogenous systemic mutant erythropoietin. Experimental Eye Research, 2012. 96: p. 36-41. doi: 10. 1016/j.exer.2012.01.006 PMID: 22306016
21. Sullivan T. and Rex T., Systemic gene delivery protects the photoreceptors in the retinal degeneration slow mouse. Neurochemical Research, 2011. 36(4): p. 613-618. doi: 10.1007/s11064-010-0272-6PMID: 20924671
22. Tsai J., Wu L., Worgul B., Forbes M., and Cao J., Intravitreal administration of erythropoietin and preservation of retinal ganglion cells in an experimental rat model of glaucoma. Current Eye Research, 2005. 30: p. 1025-1031. PMID: 16282136
23. Weishaupt J., Rohde G., Polking E., Siren A.-L., Ehrenreich H., and Bahr M., Effect of erythropoietin on axotomy-induced apoptosis in rat retinal ganglion cells. Investigative Ophthalmology and Visual Science, 2004. 45: p. 1514-1522. PMID: 15111610
24. Zhong L., Bradley J., Schubert W., Ahmed E., Adamis A., Shima D., et al., Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Investigative Ophthalmology and Visual Science, 2007. 48: p. 1212-1218. PMID: 17325165
25. Bond W., Hines-Beard J., GoldenMerry Y., Davis M., Farooque A., Sappington R., et al., Virus-mediated EpoR76E therapy slows optic nerve axonopathy in experimental glaucoma. Molecular Therapy, 2016. 24: p. 230-239. doi: 10.1038/mt.2015.198 PMID: 26502777
26. Hines-Beard J., Desai S., Haag R., Esumi N., D'Surney L., Parker S., et al., Identification of a therapeutic dose of continuously delivered erythropoietin in the eye using an inducible promoter system. Current Gene Therapy, 2013. 13: p. 275-281. PMID: 23773177
27. Bricker-Anthony C., D'Surney L., Lunn B., Hines-Beard J., Jo M., Bernando-Colon A., et al., Erythropoietin can both promote and prevent retinal damage after eye trauma. Optometry and Visual Science,2016. Epub.
28. Bricker-Anthony C., Hines-Beard J., and Rex T., Molecular changes and vision loss in a mouse model of closed-globe blast trauma. Investigative Ophthalmology and Visual Science, 2014. 55: p. 4853-4862. doi: 10.1167/iovs.14-14353 PMID: 24994864
29. de Lucas Cerrillo A., Bond W., and Rex T., Safety and angiogenic effects of systemic gene delivery of a modified erythropoietin. Gene Therapy, 2015. 22: p. 365-373. doi: 10.1038/gt.2015.12 PMID: 25716531
30. Illing M., Rajan R., Bence N., and Kopito R., A rhodopsin mutant linked to autosomal dominant retinitis pigmentosa is prone to aggregate and interacts with the ubiquitin proteasome system. Journal of Biological Chemistry, 2002. 277: p. 34150-34160. PMID: 12091393
31. Sung C., Davenport C., and Nathans J., Rhodopsin mutations responsible for autosomal dominant retinitis pigmentosa. Clustering of functional classes along the polypeptide chain. Journal of Biological Chemistry, 1993. 268: p. 26645-26649. PMID: 8253795
32. Haeri M. and Knox B., Rhodopsin mutant P23H destabilizes rod photoreceptor disk membranes. PLoS One, 2012. 7: p. e30101. doi: 10.1371/journal.pone.0030101 PMID: 22276148
33. Price B., Sandoval I., Chan F., Nichols R., Roman-Sanchez R., Wensel T., et al., Rhodopsin gene expression determines rod outer segment size and rod cell resistance to a dominant-negativeneurodegeneration mutant. PLoS One, 2012. 7: p. e49889. doi: 10.1371/journal.pone.0049889 PMID: 23185477
34. Gorbatyuk M., Gorbatyuk O., LaVail M., Lin J., Hauswirth W., and Lewin A., Functional rescue of P23H rhodopsin photoreceptors by gene delivery. Adv Exp Med Biol, 2012. 723: p. 191-197. doi: 10.1007/ 978-1-4614-0631-0-26 PMID: 22183333
35. Adekeye A., Haeri M., Solessio E., and Knox B., Ablation of the proapoptotic genes CHOP or Ask1 does not prevent or delay loss of visual function in a P23H transgenic mouse model of retinitis pigmentosa. PLoS One, 2014. 9: p. e83871. doi: 10.1371/journal.pone.0083871 PMID: 24523853
36. Chiang W., Joseph V., Yasumura D., Matthes M., Lewin A., Gorbatyuk M., et al., Ablation of Chop Transiently Enhances Photoreceptor Survival but Does Not Prevent Retinal Degeneration in Transgenic Mice Expressing Human P23H Rhodopsin. Adv Exp Med Biol, 2016. 854: p. 185-191. doi: 10.1007/ 978-3-319-17121-0-25 PMID: 26427410
37. Kaur J., Mencl S., Sahaboglu A., Farinelli P., van Veen T., Zrenner E., et al., Calpain and PARP activation during photoreceptor cell death in P23H and S334ter rhodopsin mutant rats. PLoS One, 2011. 6: p. e22181. doi: 10.1371/journal.pone.0022181 PMID: 21765948
38. Comitato A., Sanges D., Rossi A., Humphries M., and Marigo V., Activation of Bax in three models of retinitis pigmentosa. Investigative Ophthalmology & Vision Science, 2014. 55: p. 3555-3562.
39. Sizova O., Shinde V., Lenox A., and Gorbatyuk M., Modulation of cellular signaling pathways in P23H rhodopsin photoreceptors. Cell Signaling, 2014. 26: p. 665-672.
40. Ozaki T., Ishiguro S., Hirano S., Baba A., Yamashita T., Tomita H., et al., Inhibitory peptide of mitochondrial μ-calpain protects against photoreceptor degeneration in rhodopsin transgenic S334ter and P23H rats. PLoS One, 2013. 8: p. e71650. doi: 10.1371/journal.pone.0071650 PMID: 23951212
41. Hempel C., Hoyer N., Kildemoes A., Jendresen C., and Kurtzhals J., Systemic and Cerebral Vascular Endothelial Growth Factor Levels Increase in Murine Cerebral Malaria along with Increased Calpain and Caspase Activity and Can be Reduced by Erythropoietin Treatment. Frontiers in Immunology, 2014. 5: p. 291. doi: 10.3389/fimmu.2014.00291 PMID: 24995009
42. Jantzie L., Winer J., Corbett C., and Robinson S., Erythropoietin Modulates Cerebral and Serum Degradation Products from Excess Calpain Activation following Prenatal Hypoxia-Ischemia. Developmental Neuroscience, 2016. 38: p. 15-26. doi: 10.1159/000441024 PMID: 26551007
43. McGill TJ, Prusky GT, Douglas RM, Yasumura D, Matthes MT, Lowe RJ, Duncan JL, Yang H, Ahern K, Daniello KM, Silver B, LaVail MM. Discordant anatomical, electrophysiological, and visual behavioral profiles of retinal degeneration in rat models of retinal degenerative disease. Invest Ophthalmol Vis Sci 2012; 53: 6232-6244. doi: 10.1167/iovs.12-9569 PMID: 22899760